专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20040039211A1 Tetrapyrroles 审中-公开
标题翻译：四吡咯
公开(公告)号：US20040039211A1
公开(公告)日：2004-02-26
申请号：US10424150
申请日：2003-04-28
申请人： DUKE UNIVERSITY AND NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
发明人： Irwin Fridovich , Ines Batinic-Haberle , Ivan Spasojevic , James D. Crapo , Brian J. Day
IPC分类号： C07D43/14 , C07H017/02
CPC分类号： C07D207/456 , C07D487/22
摘要： The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.
摘要翻译：本发明一般涉及一种调节生理和病理过程的方法，特别涉及一种调节氧化剂细胞水平的方法，从而涉及这种氧化剂是参与者的过程。本发明还涉及适用于这些方法的化合物和组合物。

2. 发明申请

US20030202962A1 Gene therapy for effector cell regulation 审中-公开
标题翻译：基因治疗效应细胞调节
公开(公告)号：US20030202962A1
公开(公告)日：2003-10-30
申请号：US10354948
申请日：2003-01-29
申请人： National Jewish Medical and Research Center
发明人： Steve W. Dow , Robyn E. Elmslie , Terence A. Potter
IPC分类号： A61K048/00 , A61K038/19 , A61K039/02
CPC分类号： C12N15/62 , A61K38/00 , A61K39/00 , A61K39/39 , A61K48/00 , A61K2039/53 , A61K2039/55522 , C07K14/31 , C07K14/35 , C07K2319/55
摘要： The present invention provides a nucleic acid-based therapeutic composition to treat an animal with disease by controlling the activity of effector cells, including T cells, macrophages, monocytes and/or natural killer cells, in the animal. Therapeutic compositions of the present invention include superantigen-encoding nucleic acid molecules, either in the presence or absence of a cytokine-encoding nucleic acid molecule and/or chemokine-encoding nucleic acid molecules, depending upon the disease being treated. The present invention also relates to an adjuvant for use with nucleic acid-based vaccines. Adjuvant compositions of the present invention include an immunogen combined with superantigen-encoding nucleic acid molecules, either in the presence or absence of a cytokine-encoding nucleic acid molecule and/or chemokine-encoding nucleic acid molecules.
摘要翻译：本发明提供了一种基于核酸的治疗组合物，其通过控制动物中的效应细胞（包括T细胞，巨噬细胞，单核细胞和/或天然杀伤细胞）的活性来治疗具有疾病的动物。根据所治疗的疾病，本发明的治疗组合物包括在存在或不存在编码细胞因子的核酸分子和/或趋化因子编码核酸分子的情况下的编码超抗原的核酸分子。本发明还涉及用于与基于核酸的疫苗一起使用的佐剂。在存在或不存在编码细胞因子的核酸分子和/或编码趋化因子的核酸分子的情况下，本发明的佐剂组合物包括与超抗原编码核酸分子组合的免疫原。

3. 发明申请

US20030148445A1 TALL-1 nucleic acid molecules, proteins, receptors and methods of use thereof 审中-公开
标题翻译： TALL-1核酸分子，蛋白质，受体及其使用方法
公开(公告)号：US20030148445A1
公开(公告)日：2003-08-07
申请号：US10216074
申请日：2002-08-09
申请人： National Jewish Medical and Research Center
发明人： Hong-Bing Shu
IPC分类号： C12P021/02 , C12N005/06 , C07K014/705 , C07K016/28
CPC分类号： C07K14/70575 , A61K38/00
摘要： The amino acid and nucleic acid sequence of a protein expressed by monocytes and macrophages, called TALL-1, are disclosed. Homologues, mimetics and antibodies that bind to TALL-1 are disclosed. Also disclosed is the TALL-1 receptor, and homologues of such receptor. The invention includes methods for regulating the interaction between TALL-1 and its receptor and for identifying compounds capable of such regulation. The invention also includes methods for regulating B lymphocyte proliferation, activation, and/or survival.
摘要翻译：公开了由单核细胞和巨噬细胞表达的蛋白质的氨基酸和核酸序列，称为TALL-1。公开了与TALL-1结合的同源物，模拟物和抗体。还公开了TALL-1受体和这种受体的同系物。本发明包括调节TALL-1与其受体之间的相互作用以及鉴定能够进行调节的化合物的方法。本发明还包括调节B淋巴细胞增殖，活化和/或存活的方法。

4. 发明申请

US20030143644A1 Product and process to regulate actin polymerization in T lymphocytes 审中-公开
公开(公告)号：US20030143644A1
公开(公告)日：2003-07-31
申请号：US10334405
申请日：2002-12-31
申请人： National Jewish Medical and Research Center
发明人： Terri H. Finkel , Moshe M. Rozdzial
IPC分类号： G01N033/567
CPC分类号： G01N33/5011 , G01N33/5008 , G01N33/502 , G01N33/5047 , G01N33/505 , G01N2510/00 , Y10S435/975
摘要： The present invention relates to methods to regulate actin polymerization in T lymphocytes involved in tumorigenesis, inflammatory responses, immune responses, allergic responses and graft rejection responses, kits to perform such assays and methods to identify regulatory reagents that specifically control actin polymerization in T lymphocytes.

5. 发明申请

US20040023941A1 Substituted porphyrins 有权
标题翻译：取代卟啉
公开(公告)号：US20040023941A1
公开(公告)日：2004-02-05
申请号：US10349171
申请日：2003-01-23
申请人： NATIONAL JEWISH MEDICAL AND RESEARCH CENTER , AEOLUS PHARMACEUTICALS, INC. , DUKE UNIVERSITY
发明人： James D. Crapo , Brian J. Day , Michael P. Trova , Polivina Jolicia F. Gauuan , Douglas B. Kitchen , Irwin Fridovich , Ines Batinic-Haberle
IPC分类号： A61K031/555 , A61K031/427 , A61K031/4196 , A61K031/4178 , A61K031/409 , C07D487/22
CPC分类号： A61K31/555 , A61K31/409 , C07D487/22 , C09B47/00
摘要： The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.
摘要翻译：本发明一般涉及一种调节生理和病理过程的方法，特别涉及一种调节氧化剂细胞水平的方法，从而涉及这种氧化剂是参与者的过程。本发明还涉及适用于这些方法的化合物和组合物。

6. 发明申请

US20030175955A1 Novel embryonic cell populations and methods to isolate such populations 有权
标题翻译：新型胚胎细胞群体和分离这些群体的方法
公开(公告)号：US20030175955A1
公开(公告)日：2003-09-18
申请号：US10218671
申请日：2002-08-13
申请人： National Jewish Medical and Research Center
发明人： Gordon M. Keller , Robert G. Hawley , Kyunghee Choi
IPC分类号： C12N005/08
CPC分类号： C12N5/0603 , A61K2035/124 , C12N5/0635 , C12N5/0636 , C12N5/0641 , C12N5/069 , C12N5/0692 , C12N2500/24 , C12N2501/105 , C12N2501/125 , C12N2501/14 , C12N2501/165 , C12N2501/22 , C12N2501/23 , C12N2501/235 , C12N2502/28 , C12N2503/02 , C12N2506/02 , C12N2510/00 , C12N2510/04
摘要： The present invention relates to novel immortalized precursor cell populations derived from embryonic stem cell populations and methods to produce such cell populations. Also disclosed is an assay to identify regulatory compounds capable of controlling cell growth for therapeutic and experimental use.
摘要翻译：本发明涉及衍生自胚胎干细胞群的新型永生化前体细胞群和产生这种细胞群的方法。还公开了一种用于鉴定能够控制细胞生长用于治疗和实验使用的调节化合物的测定法。

7. 发明申请

US20030077284A1 Product and method for treatment of conditions associated with receptor-desensitization 审中-公开
标题翻译：用于治疗与受体脱敏相关的病症的产品和方法
公开(公告)号：US20030077284A1
公开(公告)日：2003-04-24
申请号：US10218670
申请日：2002-08-13
申请人： National Jewish Medical and Research Center
发明人： Barbara J. Vilen , John C. Cambier
IPC分类号： A61K039/395
CPC分类号： G01N33/5011 , A61K2039/505 , C07K16/28 , C07K16/2803 , C07K2317/76 , G01N33/5008 , G01N33/502 , G01N33/5041 , G01N33/5047 , G01N33/5052 , G01N33/5091 , G01N33/566 , Y10S514/885
摘要： Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.
摘要翻译：多重免疫识别受体（MIRR）受体家族，特别是B细胞抗原受体（BCR），前B细胞受体（pre-BCR），前B细胞受体（pro-BCR）， Ig Fc受体（FcR）和NK受体可以与其相关联的换能器物理分离。本发明描述了用于模拟用于受体脱敏的目的的这种解离/去稳定化的调节化合物和方法，以及治疗其中期望受体脱敏或可选的增强或延长的受体致敏的条件。还公开了用于增强或延长受体致敏的化合物和方法，以及用于鉴定适用于本发明方法的调节化合物的方法。

8. 发明申请

US20020187548A1 Method for identification of cell growth or differentiation factors 有权
标题翻译：鉴别细胞生长或分化因子的方法
公开(公告)号：US20020187548A1
公开(公告)日：2002-12-12
申请号：US09767893
申请日：2001-01-22
申请人： National Jewish Medical and Research Center
发明人： Gordon M. Keller , Robert G. Hawley , Kyunghee Choi
IPC分类号： C12N005/06 , G01N033/574
CPC分类号： C12N5/0603 , A61K2035/124 , C12N5/0635 , C12N5/0636 , C12N5/0641 , C12N5/069 , C12N5/0692 , C12N2500/24 , C12N2501/105 , C12N2501/125 , C12N2501/14 , C12N2501/165 , C12N2501/22 , C12N2501/23 , C12N2501/235 , C12N2502/28 , C12N2503/02 , C12N2506/02 , C12N2510/00 , C12N2510/04
摘要： The present invention relates to novel immortalized precursor cell populations derived from embryonic stem cell populations and methods to produce such cell populations. Also disclosed is an assay to identify regulatory compounds capable of controlling cell growth for therapeutic and experimental use.
摘要翻译：本发明涉及衍生自胚胎干细胞群的新型永生化前体细胞群和产生这种细胞群的方法。还公开了一种用于鉴定能够控制细胞生长用于治疗和实验使用的调节化合物的测定法。

9. 发明申请

US20040181037A1 Phosphatidyl serine receptors and uses thereof 审中-公开
标题翻译：磷脂酰丝氨酸受体及其用途
公开(公告)号：US20040181037A1
公开(公告)日：2004-09-16
申请号：US10625492
申请日：2003-07-22
申请人： National Jewish Medical and Research Center
发明人： Valerie A. Fadok , Peter M. Henson
IPC分类号： C07K014/705 , C07H021/04
CPC分类号： C07K14/705 , A61K38/00 , C07K2319/00 , Y02A50/409
摘要： Disclosed are phosphatidylserine (PS) receptors, including PS receptors from human, mouse, Drosophila melanogaster and Caenorhabditis elegans. Also disclosed are homologues of such receptors, nucleic acids encoding such receptors and homologues thereof, as well as agonist and antagonist compounds that specifically associate with and affect the activation state of such receptors. Preferred agonists and antagonists of PS receptors according to the invention include antibodies, antibody fragments and binding partners that selectively bind to such a receptor. Also disclosed are methods of making and using the PS receptors, homologues thereof, and agonist and antagonist compounds of such receptors. In particular, methods for reducing inflammation, for treating an autoimmune disease, for enhancing transplantation of tissue grafts, methods of increasing anti-tumor immunity, and methods for inhibiting viral and parasitic infections are described.
摘要翻译：公开了磷脂酰丝氨酸（PS）受体，包括来自人，小鼠，黑腹果蝇和秀丽隐杆线虫的PS受体。还公开了这种受体的同系物，编码这种受体的核酸和其同系物，以及与这些受体特异性结合并影响这些受体活化状态的激动剂和拮抗剂化合物。根据本发明的PS受体的优选激动剂和拮抗剂包括选择性结合这种受体的抗体，抗体片段和结合配偶体。还公开了制备和使用PS受体，其同系物，以及这些受体的激动剂和拮抗剂化合物的方法。具体地，描述了用于减轻炎症，用于治疗自身免疫疾病，用于增强组织移植物移植的方法，增加抗肿瘤免疫的方法，以及用于抑制病毒和寄生虫感染的方法。

10. 发明申请

US20040097454A1 Method for modulation of cell phenotype 审中-公开
标题翻译：调节细胞表型的方法
公开(公告)号：US20040097454A1
公开(公告)日：2004-05-20
申请号：US10431598
申请日：2003-05-06
申请人： University Technology Corporation , National Jewish Medical and Research Center , U.S. Government as represented by the Department of Veterans Affairs
发明人： Jane E. Reusch , Dwight J. Klemm
IPC分类号： A61K048/00 , C12Q001/68
CPC分类号： C07K14/4705 , A61K48/00
摘要： Described is a method for modulating the phenotype of a cell, and particularly, of a target cell in a patient who has or is at risk of developing a disease or condition in which is associated with dysregulation of cellular phenotype. The method includes administration of a recombinant nucleic acid molecule encoding a protein having CREB biological activity or dominant negative CREB biological activity to a patient, in such a manner that the protein is expressed in a target cell of a patient and is sufficient to modulate the phenotype of the target cell. Such a method is particularly useful in patients who have, or at risk of developing, diabetes, obesity, macrovascular disease, heart failure, osteoarthritis, and neural diseases and conditions.
摘要翻译：描述了调节具有或具有发展与细胞表型失调相关的疾病或病症的风险的患者中的细胞，特别是靶细胞的表型的方法。该方法包括向患者施用编码具有CREB生物活性或显性负CREB生物活性的蛋白质的重组核酸分子，使得蛋白质在患者的靶细胞中表达并且足以调节表型的目标细胞。这种方法在患有糖尿病，肥胖，大血管疾病，心力衰竭，骨关节炎和神经疾病和病症的风险的患者中特别有用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式